O	0	1	A
O	2	9	planned
O	9	10	,
O	11	22	prospective
O	23	33	comparison
O	34	36	of
O	37	42	short
O	42	43	-
O	43	47	term
O	48	55	quality
O	56	58	of
O	59	63	life
O	64	72	outcomes
O	73	78	among
O	79	84	older
O	85	93	patients
O	94	98	with
O	99	105	breast
O	106	112	cancer
O	113	120	treated
O	121	125	with
B-intervention	126	134	standard
I-intervention	135	147	chemotherapy
O	148	150	in
O	151	152	a
O	153	163	randomized
O	164	172	clinical
O	173	178	trial
O	179	181	vs
O	181	182	.
O	183	185	an
B-control	186	199	observational
I-control	200	205	study
O	205	206	:
O	207	212	CALGB
O	213	214	#
O	214	219	49907
O	220	223	and
O	224	225	#
O	225	231	369901
O	231	232	.

O	233	241	Patients
B-age	242	243	â‰¥
I-age	244	246	65
I-age	247	252	years
O	253	256	old
O	257	258	(
O	258	259	"
O	259	264	older
O	264	265	"
O	265	266	)
O	267	270	are
O	271	276	often
O	277	280	not
O	281	289	included
O	290	292	in
O	293	303	randomized
O	304	312	clinical
O	313	319	trials
O	320	321	(
O	321	324	RCT
O	324	325	)
O	325	326	,
O	327	330	but
O	331	335	when
O	336	340	they
O	341	344	are
O	344	345	,
O	346	350	care
O	351	353	in
O	354	356	an
O	357	360	RCT
O	361	366	might
O	367	374	improve
O	375	382	quality
O	383	385	of
O	386	390	life
O	391	392	(
O	392	395	QoL
O	395	396	)
O	396	397	.

O	398	400	We
O	401	410	conducted
O	411	412	a
O	413	424	prospective
O	425	435	comparison
O	436	438	of
O	439	442	QoL
O	443	448	among
O	449	454	older
O	455	460	women
O	461	470	receiving
O	471	479	standard
O	480	492	chemotherapy
O	493	497	from
O	498	501	the
O	502	506	same
O	507	518	cooperative
O	519	524	group
O	525	535	physicians
O	536	538	in
O	539	541	an
O	542	545	RCT
O	546	548	vs
O	548	549	.
O	550	552	an
O	553	566	observational
O	567	572	study
O	573	574	(
O	574	575	"
O	575	578	off
O	578	579	-
O	579	584	trial
O	584	585	"
O	585	586	)
O	586	587	.

B-eligibility	588	593	Older
I-eligibility	594	599	women
I-eligibility	600	604	with
I-eligibility	605	613	invasive
I-eligibility	613	614	,
I-eligibility	615	618	non
I-eligibility	618	619	-
I-eligibility	619	629	metastatic
I-eligibility	630	636	breast
I-eligibility	637	643	cancer
O	644	645	(
O	645	646	n
O	646	647	=
B-intervention-participants	647	650	150
O	651	654	RCT
O	654	655	;
B-control-participants	656	659	530
O	660	663	off
O	663	664	-
O	664	669	trial
O	669	670	)
O	671	675	were
O	676	684	included
O	684	685	.

O	686	692	Linear
O	693	698	mixed
O	698	699	-
O	699	706	effects
O	707	713	models
O	714	720	tested
O	721	733	associations
O	734	741	between
O	742	754	chemotherapy
O	755	757	on
O	757	758	-
O	759	761	vs
O	761	762	.
O	763	766	off
O	766	767	-
O	767	772	trial
O	773	776	and
O	777	784	changes
O	785	787	in
O	788	793	EORTC
O	794	795	(
O	795	803	European
O	804	816	Organisation
O	817	820	for
O	821	829	Research
O	830	833	and
O	834	843	Treatment
O	844	846	of
O	847	853	Cancer
O	854	861	Quality
O	862	864	of
O	865	869	Life
O	870	883	Questionnaire
O	883	884	)
O	885	888	QoL
O	889	895	scores
O	896	900	over
O	901	903	24
O	904	910	months
O	910	911	,
O	912	923	controlling
O	924	927	for
O	928	931	pre
O	931	932	-
O	932	941	treatment
O	942	945	QoL
O	945	946	,
O	947	950	age
O	950	951	,
O	952	961	education
O	961	962	,
O	963	968	tumor
O	969	976	factors
O	976	977	,
O	978	989	comorbidity
O	989	990	,
O	991	994	and
O	995	1000	other
O	1001	1011	covariates
O	1011	1012	.

B-outcome	1013	1026	Anthracycline
I-outcome	1027	1035	regimens
O	1036	1040	were
O	1041	1045	used
O	1046	1048	by
O	1049	1051	58
O	1051	1052	%
O	1053	1055	of
O	1056	1061	women
O	1062	1069	treated
O	1070	1072	on
O	1072	1073	-
O	1073	1078	trial
O	1079	1081	vs
O	1081	1082	.
O	1083	1085	54
O	1085	1086	%
O	1087	1089	of
O	1090	1095	those
O	1096	1103	treated
O	1104	1107	off
O	1107	1108	-
O	1108	1113	trial
O	1113	1114	.

O	1115	1120	Women
O	1121	1123	in
O	1124	1127	the
O	1128	1131	RCT
O	1132	1140	reported
O	1141	1143	an
O	1144	1152	adjusted
O	1153	1157	mean
O	1158	1166	increase
O	1167	1169	of
B-iv-cont-mean	1170	1172	13
I-iv-cont-mean	1172	1173	.
I-iv-cont-mean	1173	1174	7
I-iv-cont-mean	1175	1181	points
O	1182	1183	(
O	1183	1185	95
O	1185	1186	%
O	1187	1189	CI
O	1190	1192	10
O	1192	1193	.
O	1193	1194	2
O	1194	1195	,
O	1196	1198	17
O	1198	1199	.
O	1199	1200	1
O	1200	1201	)
O	1202	1204	in
B-outcome	1205	1211	global
I-outcome	1212	1215	QoL
I-outcome	1216	1218	at
I-outcome	1219	1221	24
I-outcome	1222	1228	months
O	1229	1230	(
O	1230	1232	vs
O	1232	1233	.
O	1234	1237	mid
O	1237	1238	-
O	1238	1247	treatment
O	1247	1248	)
O	1248	1249	,
O	1250	1255	while
O	1256	1261	women
O	1262	1269	treated
O	1270	1273	off
O	1273	1274	-
O	1274	1279	trial
O	1280	1283	had
O	1284	1288	only
O	1289	1291	an
O	1292	1300	adjusted
O	1301	1312	improvement
O	1313	1315	of
B-cv-cont-mean	1316	1317	7
I-cv-cont-mean	1317	1318	.
I-cv-cont-mean	1318	1319	0
I-cv-cont-mean	1320	1326	points
O	1327	1328	(
O	1328	1330	95
O	1330	1331	%
O	1332	1334	CI
O	1335	1336	3
O	1336	1337	.
O	1337	1338	5
O	1338	1339	,
O	1340	1342	10
O	1342	1343	.
O	1343	1344	4
O	1344	1345	;
O	1346	1347	p
O	1347	1348	=
O	1348	1349	.
O	1349	1352	007
O	1353	1356	for
O	1357	1367	difference
O	1368	1370	in
O	1371	1375	mean
O	1376	1383	changes
O	1383	1384	)
O	1384	1385	.

O	1386	1391	Women
O	1392	1394	in
O	1395	1398	the
O	1399	1402	RCT
O	1403	1406	had
O	1407	1420	significantly
O	1421	1428	greater
B-outcome	1429	1440	improvement
I-outcome	1441	1443	in
I-outcome	1444	1453	emotional
I-outcome	1454	1462	function
O	1463	1467	than
O	1468	1473	those
O	1474	1481	treated
O	1482	1485	off
O	1485	1486	-
O	1486	1491	trial
O	1491	1492	,
O	1493	1504	controlling
O	1505	1508	for
O	1509	1517	baseline
O	1517	1518	;
O	1519	1523	they
O	1524	1528	also
O	1529	1532	had
O	1533	1540	greater
B-outcome	1541	1551	reductions
I-outcome	1552	1554	in
I-outcome	1555	1562	therapy
I-outcome	1563	1567	side
I-outcome	1568	1575	effects
I-outcome	1576	1579	and
I-outcome	1580	1587	fatigue
O	1588	1590	at
O	1591	1593	24
O	1594	1600	months
O	1601	1605	than
O	1606	1611	women
O	1612	1615	off
O	1615	1616	-
O	1616	1621	trial
O	1621	1622	,
O	1623	1634	controlling
O	1635	1638	for
O	1639	1649	covariates
O	1649	1650	.

O	1651	1656	There
O	1657	1660	may
O	1661	1663	be
O	1664	1673	different
B-outcome	1674	1677	QoL
I-outcome	1678	1690	trajectories
O	1691	1694	for
O	1695	1700	older
O	1701	1706	women
O	1707	1717	undergoing
O	1718	1724	breast
O	1725	1731	cancer
O	1732	1744	chemotherapy
O	1745	1747	on
O	1747	1748	-
O	1749	1751	vs
O	1751	1752	.
O	1753	1756	off
O	1756	1757	-
O	1757	1762	trial
O	1762	1763	.

O	1764	1766	If
O	1767	1776	confirmed
O	1776	1777	,
O	1778	1781	the
O	1782	1789	results
O	1790	1797	suggest
O	1798	1802	that
O	1803	1806	the
O	1807	1812	extra
O	1813	1823	monitoring
O	1824	1827	and
O	1828	1841	communication
O	1842	1848	within
O	1849	1851	an
O	1852	1855	RCT
O	1856	1861	could
O	1862	1869	provide
O	1870	1873	the
O	1874	1888	infrastructure
O	1889	1892	for
O	1893	1906	interventions
O	1907	1909	to
O	1910	1917	address
O	1918	1926	symptoms
O	1927	1930	and
O	1931	1938	improve
O	1939	1942	QoL
O	1943	1946	for
O	1947	1950	the
O	1951	1958	growing
O	1959	1964	older
O	1965	1971	cancer
O	1972	1982	population
O	1982	1983	.
